Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
AssigneeCuremark, LLC
InventorJoan M. Fallon
Life of this patent
Estimating the term…
Abstract
A pharmaceutical preparation for the treatment of attention deficit disorders combines a therapeutically effective amount of digestive enzymes, such as chymotrypsin, and medication used to treat attention deficit disorders, such as Ritalin®, Concerta®, Adderall® and Strattera®. The preparation may be in the form of a tablet, capsule or time released formula in order to reduce the amount of pills per dosage. The pharmaceutical preparation ameliorates the symptoms of the attention deficit disorder. The preparation has a stabilizing matrix containing a solidified microcrystalline cellulose which captures and protects therapeutically effective amounts of digestive enzyme particles within the stabilizing matrix.
Claims27
1-22. (canceled)
A method of treating Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a first class of medication and a pharmaceutical preparation comprising digestive enzymes for at least six months, wherein the pharmaceutical preparation is effective to reduce the amount of the first class of medication used to treat ADD or ADHD in the subject;
- wherein the digestive enzymes comprise a protease, an amylase and a lipase, and wherein the first class of medication is selected from the group consisting of an amphetamine, an amphetamine salt, an atomoxetine HCl, and a combination thereof.
A pharmaceutical preparation, comprising
- (a) a therapeutically effective amount of a first class of medication used to treat Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD);
- and
- (b) digestive enzymes comprising protease, amylase and lipase.
A method for the manufacture of a pharmaceutical preparation by direct compression comprising the steps of:
- forming an active blend by blending an intimate admixture of silicified microcrystalline cellulose and a therapeutic agent comprising one or more digestive enzymes and one or more medications used to treat attention deficit disorder;
- forming a color blend by blending an intimate admixture of a plurality of pharmaceutically acceptable dyes and a silicified microcrystalline cellulose;
- combining the active blend, the color blend and a disintegrant into a preblend;
- adding a lubricant to the preblend to form a final blend;
- and compressing the final blend to form the pharmaceutical preparation.
Dependencies are inferred from the claim text.